Skip to content

S. 2062 · 119th Congress (2025–2027)

RAPID Reserve Act

A bill to improve supply chain resiliency for critical drug products with vulnerable supply chains and ensure that reserves of critical drugs and active pharmaceutical ingredients are maintained to prevent supply disruptions in the event of drug shortages or public health emergencies.

CRS summary not yet available.

Referred to committee

Latest actionReferred to committee

This bill’s path

This is S. 2062’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

Sponsor
Sen. Gary C. Peters (D-MI)
Cosponsors
3 cosponsors

3 original · 0 later

  1. Sen. Marsha Blackburn (R-TN)· Original · Jun 12, 2025
  2. Sen. Ted Budd (R-NC)· Original · Jun 12, 2025
  3. Sen. Tim Kaine (D-VA)· Original · Jun 12, 2025
Policy area
Health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. Latest

    Referred to committee

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Sources

Committees

  1. SenateHealth, Education, Labor, and PensionsReferred Jun 12, 2025

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Titles (3)
  1. RAPID Reserve Act

    Display title, Short title · Introduced in Senate

  2. Rolling Active Pharmaceutical Ingredient and Drug Reserve Act

    Short title · Introduced in Senate

  3. A bill to improve supply chain resiliency for critical drug products with vulnerable supply chains and ensure that reserves of critical drugs and active pharmaceutical ingredients are maintained to prevent supply disruptions in the event of drug shortages or public health emergencies.

    Official title · Introduced in Senate